Information Analysis Inc (IAIC) 0.1550 $IAIC Faith M.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Information Analysis Inc (IAIC) 0.1550 $IAIC

Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who
PR Newswire - Tue Apr 26, 10:49AM CDT
Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who with the 2015-2016 Lifetime Achievement award as a result of fifty years of excellence in the field of Healthcare.

Information Analysis Inc. Reports Profitable Results for 2015
Marketwired - Wed Mar 30, 9:52AM CDT
Information Analysis Incorporated. (OTC PINK: IAIC) today reported results for the year ended December 31, 2015. Revenues were up 7% to $6,214,000, compared to revenues of $5,784,000 for the same period in 2014. The information technology services company reported net income of $78,000, or $0.01 per share basic and diluted, compared to a net loss of $30,000, or $(0.00) per share basic and diluted, reported for the comparable 2014 period.

Information Analysis (IAI) Announces Director of Cyber Security
ACCESSWIRE - Mon Feb 08, 12:01PM CST
FAIRFAX, VA / ACCESSWIRE / February 8, 2016 / Information Analysis Incorporated (OTC: IAIC), a business information technology services company, is pleased to announce the hiring of Irene M. Carter as its Director of Cyber Security Practice. In her role as Director, Ms. Carter will be actively involved in business development of a new technology practice for IAI centered on cyber security, secure communications and information protection.

MacAulay-Brown Wins Prime Award on Cyber Systems Technical Area Tasks IDIQ
GlobeNewswire - Mon Dec 07, 9:35AM CST
MacAulay-Brown, Inc. (MacB), a leading National Security company delivering advanced engineering services and product solutions to Defense, Intelligence, Special Operations Forces, Homeland Security and Federal agencies, announced today that it has been awarded a prime contract on the Cyber Security and Information Systems Technical Area Tasks (CS TAT) IDIQ from the Air Force Installation Contracting Agency Operating Location, Offutt AFB, Nebraska, for the Defense Technical Information Center (DTIC) Information Analysis Center. The five-year, multiple-award Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract is valued at $5 billion. MacB is one of 10 defense contract winners that can bid on individual tasks estimated to be greater than $3.5 million, and work will be done at a variety of locations.

Research and Markets: Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:47PM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fg5ld/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering.

Research and Markets: Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:28PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4nt8z/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering.

Research and Markets: Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vffjm/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering.

Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zql59x/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering. This Streptococcal Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcal Infections. This report provides information on the therapeutic development based on the Streptococcal Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcal Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcal Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Streptococcal Infections Overview - Streptococcal Infections Pipeline Therapeutics - Streptococcal Infections Therapeutics under Development by Companies - Streptococcal Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcal Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcal Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcal Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcal Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcal Infections - Discontinued Products - Streptococcal Infections - Dormant Products - Companies Involved in Therapeutics Development for Streptococcal Infections For more information visit http://www.researchandmarkets.com/research/zq...eptococcal

Streptococcus Pneumoniae Infection-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjgw7s/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection-Pipeline Insights" report to their offering. This Streptococcus Pneumoniae Infection-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcus Pneumoniae Infection. This report provides information on the therapeutic development based on the Streptococcus Pneumoniae Infection dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Streptococcus Pneumoniae Infection Overview - Streptococcus Pneumoniae Infection Pipeline Therapeutics - Streptococcus Pneumoniae Infection Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcus Pneumoniae Infection Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcus Pneumoniae Infection Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcus Pneumoniae Infection Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcus Pneumoniae Infection - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcus Pneumoniae Infection - Discontinued Products - Streptococcus Pneumoniae Infection - Dormant Products - Companies Involved in Therapeutics Development for Streptococcus Pneumoniae Infection For more information visit http://www.researchandmarkets.com/research/rj...eptococcus

Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkz4d/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering. This Clostridium Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Clostridium Infections. This report provides information on the therapeutic development based on the Clostridium Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Clostridium Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Clostridium Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Clostridium Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Clostridium Infections Overview - Clostridium Infections Pipeline Therapeutics - Clostridium Infections Therapeutics under Development by Companies - Clostridium Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Clostridium Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Clostridium Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Clostridium Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Clostridium Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Clostridium Infections - Discontinued Products - Clostridium Infections - Dormant Products - Companies Involved in Therapeutics Development for Clostridium Infections For more information visit http://www.researchandmarkets.com/research/9m...lostridium

Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trbvmg/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering. This Diabetic Complications-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Diabetic Complications. This report provides information on the therapeutic development based on the Diabetic Complications dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Complications - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Diabetic Complications pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Diabetic Complications and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Diabetic Complications Overview - Diabetic Complications Pipeline Therapeutics - Diabetic Complications Therapeutics under Development by Companies - Diabetic Complications Late Stage Products (Filed and Phase III) - Comparative Analysis - Diabetic Complications Mid Clinical Stage Products (Phase II) - Comparative Analysis - Diabetic Complications Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Diabetic Complications Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Diabetic Complications - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Diabetic Complications - Discontinued Products - Diabetic Complications - Dormant Products - Companies Involved in Therapeutics Development for Diabetic Complications For more information visit http://www.researchandmarkets.com/research/trbvmg/diabetiC

Particle Size Analyzer Market Global Distribution & Development Analysis
PRWeb - Thu May 14, 12:30PM CDT
This is a professional and in-depth study on the current state of the particle size analyzer industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, Revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The particle size analyzer industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 158 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This report also states import/export consumption, supply and demand figures, cost price and Revenue gross margins. Browse complete research report @ http://www.deepresearchreports.com/115211.html .

Information Analysis (IAI) Announces Reseller Agreement to Provide Secure Encryption Solutions for the Mobile World
ACCESSWIRE - Mon Jan 26, 8:00AM CST
FAIRFAX, VA / ACCESSWIRE / January 26, 2015 / Fairfax-based Information Analysis Incorporated (OTCQB: IAIC) a provider of information technology and professional services to the federal government and commercial marketplace, said it has signed an agreement to be a reseller of Protected Mobility products. Under the deal, IAI will leverage its existing customer relationships and proven presence in the government arena to provide sales and IT services to a broad base of customers in both the government and select commercial areas.

Information Analysis Inc. Reports New Contracts in the Third Quarter
Marketwired - Wed Nov 12, 10:42AM CST
Information Analysis Inc. (OTCBB: IAIC) today reported results for its third fiscal quarter ended September 30, 2014. Revenues were $1,357,000 compared to $3,218,000 reported in the third quarter 2013. The information technology services company reported net income of $28,000, or $0.00 per share basic and diluted, compared to net income of $108,000 or $0.01 per share basic and diluted, in the third quarter 2013.

Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax(TM)-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
PR Newswire - Fri Oct 31, 7:00AM CDT
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. In addition, the USACC has contracted for clinical evaluation of the VesiculoVax(TM) Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has been made with Battelle Memorial Institute through the Chemical, Biological, Radiological, & Nuclear Defense Information Analysis Center (CBRNIAC) contract, a Defense Technical Information Center (DTIC®) owned, Indefinite Delivery Indefinite Quantity (ID/IQ) contract vehicle for providing comprehensive scientific and technical research and analysis supporting the Department of Defense CBRN and Homeland Defense communities. Battelle has contracted with Profectus for manufacturing and clinical evaluation and with Charles River Laboratories and Biologics Consulting Group for preclinical testing and IND preparation, respectively.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading